MA49560B1 - Composés cétoniques bicycliques et leurs procédés d'utilisation - Google Patents

Composés cétoniques bicycliques et leurs procédés d'utilisation

Info

Publication number
MA49560B1
MA49560B1 MA49560A MA49560A MA49560B1 MA 49560 B1 MA49560 B1 MA 49560B1 MA 49560 A MA49560 A MA 49560A MA 49560 A MA49560 A MA 49560A MA 49560 B1 MA49560 B1 MA 49560B1
Authority
MA
Morocco
Prior art keywords
methods
ketone compounds
bicyclic ketone
compounds
ring
Prior art date
Application number
MA49560A
Other languages
English (en)
Other versions
MA49560A (fr
Inventor
Huifen Chen
Snahel Patel
Guiling Zhao
Gregory Hamilton
Craig Stivala
Blake Daniels
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA49560A publication Critical patent/MA49560A/fr
Publication of MA49560B1 publication Critical patent/MA49560B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés représentés par la formule générale i : (i) dans laquelle r1, le cycle a et le cycle b sont tels que décrits dans la description, ainsi que des compositions pharmaceutiques comprenant lesdits composés et des procédés d'utilisation de ces composés.
MA49560A 2017-07-14 2018-07-12 Composés cétoniques bicycliques et leurs procédés d'utilisation MA49560B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762532767P 2017-07-14 2017-07-14
PCT/EP2018/068998 WO2019012063A1 (fr) 2017-07-14 2018-07-12 Composés cétoniques bicycliques et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA49560A MA49560A (fr) 2020-05-20
MA49560B1 true MA49560B1 (fr) 2024-05-31

Family

ID=62916677

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49560A MA49560B1 (fr) 2017-07-14 2018-07-12 Composés cétoniques bicycliques et leurs procédés d'utilisation

Country Status (30)

Country Link
US (3) US11098058B2 (fr)
EP (2) EP4397309A3 (fr)
JP (2) JP7258843B2 (fr)
KR (2) KR102664604B1 (fr)
CN (2) CN110914271B (fr)
AR (1) AR112274A1 (fr)
AU (3) AU2018300043B2 (fr)
BR (1) BR112020000771A2 (fr)
CA (2) CA3185865A1 (fr)
CL (1) CL2020000101A1 (fr)
CO (1) CO2020000134A2 (fr)
CR (1) CR20200002A (fr)
DK (1) DK3652178T3 (fr)
ES (1) ES2973661T3 (fr)
FI (1) FI3652178T3 (fr)
HR (1) HRP20240354T1 (fr)
HU (1) HUE065793T2 (fr)
IL (2) IL271981B (fr)
LT (1) LT3652178T (fr)
MA (1) MA49560B1 (fr)
PE (1) PE20200793A1 (fr)
PH (1) PH12020500105A1 (fr)
PL (1) PL3652178T3 (fr)
PT (1) PT3652178T (fr)
RS (1) RS65308B1 (fr)
SG (1) SG11202000333UA (fr)
SI (1) SI3652178T1 (fr)
TW (1) TWI805595B (fr)
UA (1) UA125448C2 (fr)
WO (1) WO2019012063A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201831478A (zh) * 2016-12-02 2018-09-01 瑞士商赫孚孟拉羅股份公司 雙環醯胺化合物及其使用方法
MA49560B1 (fr) 2017-07-14 2024-05-31 Hoffmann La Roche Composés cétoniques bicycliques et leurs procédés d'utilisation
SG11202002877RA (en) 2017-10-31 2020-04-29 Hoffmann La Roche Bicyclic sulfones and sulfoxides and methods of use thereof
CN113302193A (zh) * 2019-01-11 2021-08-24 豪夫迈·罗氏有限公司 双环吡咯并三唑酮化合物及其使用方法
WO2021198981A1 (fr) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Composés antiviraux et leurs utilisations
CN115768744B (zh) 2020-04-27 2024-06-28 奧土择破利悟 作为ubr盒结构域配体的化合物
KR20230165238A (ko) * 2021-04-02 2023-12-05 제넨테크, 인크. 비시클릭 케톤 화합물 제조 공정
WO2023039795A1 (fr) * 2021-09-16 2023-03-23 维泰瑞隆（北京）生物科技有限公司 Inhibiteur de la kinase rip1 et son utilisation
WO2023225041A1 (fr) * 2022-05-19 2023-11-23 Merck Sharp & Dohme Llc Inhibiteurs de ripk1 et procédés d'utilisation
AU2024312554A1 (en) * 2023-06-19 2025-12-18 F. Hoffmann-La Roche Ag Process for the preparation of a chiral pyrrolo triazole alcohol

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620508A1 (de) 1965-07-23 1969-09-18 Thomae Gmbh Dr K Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3948903A (en) 1972-12-15 1976-04-06 Parke, Davis & Company Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (fr) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipides et composés tensio-actifs en phase aqueuse
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8610530D0 (en) 1986-04-30 1986-06-04 Fbc Ltd Herbicides
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
EP0652775B1 (fr) 1992-07-27 2000-04-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Ciblage de liposomes sur la barriere hemato-encephalique
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
EP1007042A4 (fr) 1997-06-13 2001-07-04 Sugen Inc Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine
AU2001234958A1 (en) * 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
WO2002017930A2 (fr) 2000-08-30 2002-03-07 The Board Of Trustees Of The Leland Stanford Junior University Agents bloquants des glucocorticoides pour augmenter la permeabilite de la barriere hemato-encephalique
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
KR101050700B1 (ko) 2002-08-26 2011-07-20 다케다 야쿠힌 고교 가부시키가이샤 칼슘 수용체 조절 화합물 및 이의 용도
AU2003302676A1 (en) 2002-12-03 2004-06-23 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
US7417152B2 (en) 2003-05-02 2008-08-26 Elan Pharmaceuticals, Inc. 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases
EP1663239A4 (fr) 2003-09-10 2008-07-23 Cedars Sinai Medical Center Administration assistee par les canaux potassiques d'agents a travers la barriere hemato-encephalique
WO2006114706A1 (fr) 2005-04-26 2006-11-02 Pfizer Limited Derives de triazole utilises comme antagonistes de la vasopressine
EP2083009A1 (fr) 2008-01-22 2009-07-29 Grünenthal GmbH Composés tétrahydroimidazopyridine substitués et leur utilisation en tant que médicament
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN101824036A (zh) 2009-03-05 2010-09-08 上海恒瑞医药有限公司 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
JO3156B1 (ar) 2009-07-09 2017-09-20 Novartis Ag ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا
KR20140096100A (ko) 2011-11-03 2014-08-04 에프. 호프만-라 로슈 아게 이환 피페라진 화합물
BR112014026176A2 (pt) 2012-05-22 2017-06-27 Hoffmann La Roche dipiridilaminas substituídas e usos das mesmas
MX2015009270A (es) 2013-01-18 2015-10-30 Hoffmann La Roche Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
TWI648273B (zh) * 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（三）
PE20161063A1 (es) 2013-05-01 2016-10-22 Hoffmann La Roche Compuestos de biheteroarilo y usos de los mismos
WO2014177524A1 (fr) 2013-05-01 2014-11-06 F. Hoffmann-La Roche Ag Pyrimidines à substitution hétérocycloalkyle liées à c et leurs utilisations
AU2014287471C1 (en) 2013-07-10 2019-11-28 Vertex Pharmaceuticals Incorporated Fused piperidine amides as modulators of ion channels
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
EP3122751B1 (fr) 2014-03-26 2019-10-30 F.Hoffmann-La Roche Ag Composés condensés de [1,4]diazépine en tant qu'inhibiteurs d'autotaxine (atx) et de production d'acide lysophosphatidique (lpa)
BR112017003546A2 (pt) 2014-08-21 2017-12-05 Glaxosmithkline Ip Dev Ltd amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
WO2016128908A1 (fr) * 2015-02-12 2016-08-18 Advinus Therapeutics Limited Composés bicycliques, compositions et applications médicinales correspondantes
CN107406462B (zh) 2015-03-09 2020-11-10 豪夫迈·罗氏有限公司 三环dlk抑制剂及其用途
TWI788830B (zh) 2015-07-02 2023-01-01 瑞士商赫孚孟拉羅股份公司 雙環內醯胺及其使用方法
CN108602809B (zh) 2015-12-04 2022-09-30 戴纳立制药公司 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂
US10961258B2 (en) 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
SG10201913587WA (en) 2016-02-05 2020-02-27 Denali Therapeutics Inc Inhibitors of receptor-interacting protein kinase 1
TW201831478A (zh) 2016-12-02 2018-09-01 瑞士商赫孚孟拉羅股份公司 雙環醯胺化合物及其使用方法
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
EP3566471B1 (fr) 2017-01-05 2022-09-28 Microsoft Technology Licensing, LLC Simulation audio pour jeux vidéo avec chemins de propagation indirects
MA49560B1 (fr) 2017-07-14 2024-05-31 Hoffmann La Roche Composés cétoniques bicycliques et leurs procédés d'utilisation
CR20200151A (es) * 2017-10-11 2020-05-23 Hoffmann La Roche Compuestos bicíclicos y métodos de utilización de los mismos
SG11202002877RA (en) 2017-10-31 2020-04-29 Hoffmann La Roche Bicyclic sulfones and sulfoxides and methods of use thereof

Also Published As

Publication number Publication date
BR112020000771A2 (pt) 2020-07-14
IL271981B (en) 2022-09-01
CA3067944A1 (fr) 2019-01-17
HRP20240354T1 (hr) 2024-06-07
US20210139504A1 (en) 2021-05-13
AU2021204369A1 (en) 2021-07-29
US20240300974A1 (en) 2024-09-12
AU2023203292B2 (en) 2025-01-30
KR20200030558A (ko) 2020-03-20
PE20200793A1 (es) 2020-08-10
UA125448C2 (uk) 2022-03-09
MA49560A (fr) 2020-05-20
IL271981A (en) 2020-02-27
WO2019012063A1 (fr) 2019-01-17
EP3652178A1 (fr) 2020-05-20
AU2018300043B2 (en) 2021-04-01
LT3652178T (lt) 2024-04-10
PL3652178T3 (pl) 2024-05-06
EP3652178B1 (fr) 2024-01-24
JP7258843B2 (ja) 2023-04-17
JP2023085449A (ja) 2023-06-20
KR20240065201A (ko) 2024-05-14
ES2973661T3 (es) 2024-06-21
TWI805595B (zh) 2023-06-21
US20190100530A1 (en) 2019-04-04
RU2020106375A3 (fr) 2022-03-25
JP2020526549A (ja) 2020-08-31
TW201920149A (zh) 2019-06-01
AU2018300043A1 (en) 2020-01-16
US11834461B2 (en) 2023-12-05
SG11202000333UA (en) 2020-02-27
HUE065793T2 (hu) 2024-06-28
CR20200002A (es) 2020-02-10
KR102664604B1 (ko) 2024-05-14
CL2020000101A1 (es) 2020-07-17
CN110914271A (zh) 2020-03-24
RU2020106375A (ru) 2021-08-16
SI3652178T1 (sl) 2024-05-31
US11098058B2 (en) 2021-08-24
CN110914271B (zh) 2024-12-10
EP4397309A2 (fr) 2024-07-10
FI3652178T3 (fi) 2024-03-19
JP7734163B2 (ja) 2025-09-04
DK3652178T3 (da) 2024-03-25
AU2023203292A1 (en) 2023-06-22
PT3652178T (pt) 2024-03-18
EP4397309A3 (fr) 2024-09-04
CN119613408A (zh) 2025-03-14
CO2020000134A2 (es) 2020-01-17
CA3067944C (fr) 2023-03-14
RS65308B1 (sr) 2024-04-30
IL294961A (en) 2022-09-01
AR112274A1 (es) 2019-10-09
CA3185865A1 (fr) 2019-01-17
PH12020500105A1 (en) 2020-11-09
NZ760749A (en) 2024-08-30

Similar Documents

Publication Publication Date Title
WO2019035864A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins
MA55131B1 (fr) Nouveaux composés hétérocycliques
MA51530B1 (fr) Composés cycliques fondus
MA48594B1 (fr) Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a
MA41562A1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA38432A1 (fr) Nouveaux dérivés d'octahydro-pyrrolo [3,4-c]-pyrrole et analogues de ceux-ci servant d'inhibiteurs d'autotaxine
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA40290A1 (fr) Agents immunorégulateurs
MA64323B1 (fr) Inhibiteurs de nlrp3
CY1117681T1 (el) Ρυθμιστες 2,3-διοξυγενασης ινδολοαμινης και μεθοδοι χρησης αυτων
MA46101B1 (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA42230A (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
TW200730515A (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA46490A1 (fr) Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
MA39374A1 (fr) Triterpénoïdes présentant une activité d'inhibition de la maturation du vih, substitués en 3ème position par un cycle non aromatique portant un substituant halogénoalkyle
MA34094B1 (fr) Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
FR3078704B1 (fr) Derives d'isohexide et leurs utilisations